Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. TMCI
TMCI logo

TMCI Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Treace Medical Concepts, Inc (TMCI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
4.190
1 Day change
4.49%
52 Week Range
7.780
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Treace Medical Concepts, Inc (TMCI) is not a strong buy at the moment for a beginner investor with a long-term horizon. While the company has launched a new product with potential market expansion benefits, the technical indicators and options data do not suggest a compelling entry point. Additionally, there is no significant trading activity from insiders, hedge funds, or influential figures to support a strong buy decision.

Technical Analysis

The MACD is above 0 and positively contracting, indicating a mild bullish trend. The RSI is neutral at 66.951, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading near its resistance level (R1: 4.339), which could limit immediate upside potential.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The low put-call ratios indicate a bullish sentiment in the options market, but the overall volume is low, suggesting limited activity.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
1
Buy
10

Positive Catalysts

  • This could enhance the company's market share and procedural utilization in the foot and ankle market.

Neutral/Negative Catalysts

  • The stock has a 50% chance to decline by -1.61% in the next day and -2.41% in the next week based on historical candlestick patterns. Additionally, there is no recent congress trading data or significant insider/hedge fund activity to support a strong buy.

Financial Performance

No financial data is available for analysis. The latest quarter's financial performance could not be assessed.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target changes are available for TMCI.

Wall Street analysts forecast TMCI stock price to rise
6 Analyst Rating
Wall Street analysts forecast TMCI stock price to rise
1 Buy
4 Hold
1 Sell
Hold
Current: 4.010
sliders
Low
3
Averages
4.87
High
7.5
Current: 4.010
sliders
Low
3
Averages
4.87
High
7.5
Lake Street
Buy
downgrade
$7
AI Analysis
2026-03-02
Reason
Lake Street
Price Target
$7
AI Analysis
2026-03-02
downgrade
Buy
Reason
Lake Street lowered the firm's price target on Treace Medical to $7 from $7.50 and keeps a Buy rating on the shares. Treace's Q4 was slightly favorable to preliminary results and while 2026 guidance was "a mixed bag," the firm sees little downside in shares from here and "a favorable risk-reward for patient investors," the analyst says after earnings.
UBS
Neutral
downgrade
2026-03-02
Reason
UBS
Price Target
2026-03-02
downgrade
Neutral
Reason
UBS lowered the firm's price target on Treace Medical to $2.25 from $2.50 and keeps a Neutral rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for TMCI
Unlock Now

People Also Watch